Clinical Trial: A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Study Type: INTERVENTIONAL
Official Title: A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Brief Summary:
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients.The main questions the study aims to answer are:can a safe dose of JNJ-90009530 be determined that is safe and well tolerated by patients.will JNJ-90009530 help patients achieve a response and for how long?
Read more